Skip to content

Diagnostic value of 68GA-FAPI PET imaging in ovarian cancer

Diagnostic value of 68GA-FAPI PET imaging in ovarian cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053171
Enrollment
Unknown
Registered
2021-11-13
Start date
2021-11-08
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Gold Standard:Biopsy or surgical pathology diagnosed malignant ovarian tumor
Index test:68GA-FAPI&#32
imaging

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed patients with clinical suspicion of ovarian cancer; 2. Other situations that require 68Ga-FAPI imaging (including those who cannot be differentiated from benign and malignant only by conventional imaging and 18F-FDG imaging); 3. If confirmed by pathology or follow-up, reliable pathological results can be obtained.

Exclusion criteria

Exclusion criteria: 1. Those with a history of severe alcohol allergy; 2. Patients who are unsuitable, unable and unwilling to cooperate with the completion of relevant examinations and follow-up; 3. Patients with severe liver and kidney damage.

Design outcomes

Primary

MeasureTime frame
Maximum standard intake value;Tumor-to-background ratios;

Countries

China

Contacts

Public ContactYao Liangqing

Obstetrics and Gynecology Hospital of Fudan University

yaoliangqing@163.com+86 18002454522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026